EU slaps Teva with 463m euro fine for abusing market position
The European Commission has fined Teva Pharmaceuticals €462.6m (US$503m) for abusing its dominant market position by blocking competition to its multiple sclerosis drug, Copaxone. This case is the largest antitrust fine imposed on a pharmaceutical company in recent years, surpassing a €288m fine against Servier in 2014. According to the commission, Teva misused the patent […]
EU slaps Teva with 463m euro fine for abusing market position Read More »